Patrys Ltd (ASX:PAB) managing director and CEO Dr James Campbell talks with Proactive’s Elisha Newell about two new patents that advance protection for the company’s antibody technology through to 2039. The first patent, co-filed with Yale University, is the first US patent to be granted specifically for PAT-DX1 and PAT-DX3, while the second covers deoxymabs with nanocarriers — a combination that could provide a powerful new approach for treating cancer. Dr Campbell highlights the growing opportunity in the cancer therapeutics space and says Patrys looks forward to its first-in-human clinical trial for PAT-DX1 next year.
Patrys secures US patents for antibody technology
